Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
In the world economic growth, the Glucagon Industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Glucagon market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2019, SMI analysts believe that in the next few years, Glucagon market size will be further expanded, we expect that by 2024, The market size of the Glucagon will reach XXX million $.
Glucagon is a hormone produced by alpha cells found in the pancreas is involved in regulating the blood sugar levels. It prevents the dropping down of blood sugar levels and also promotes the secretion of glucose from an amino acid. Glucagon is also used as a medication for treating various medical conditions and manufactured from proglucagon, encoded by the GCG gene process. Glucagon keeps the blood sugar level within the set levels and it can be administered by injection to restore the glucose lowered by insulin. Thus, Glucagon is crucial for an accurate blood sugar level. Moreover, Glucagon is widely used across the cardiogenic shock, emergency kits, diagnostic and motility, and other fields.
Rising prevalence of diabetes around the globe is predominantly fueling the market growth of glucagon. World Health Organization estimates that diabetes was the seventh leading cause of death in 2016. In 2016, an estimated 1.6 million deaths were directly caused by diabetes. Growth in the geriatric population, increasing per capita income, and improving healthcare facilities are some of the other factors augmenting the market growth of the glucagon over the forecast period.
From the geographical perspective, North America is expected to gain significant growth over the forecast period due to rising healthcare expenditure and the rapid introduction of advanced technologies in the region. For instance, in July 2019, the FDA has approved GVOKE, a glucagon injection for the treatment of low blood sugar (severe hypoglycemia) in children with diabetes who are at least two years of age. Xeris Pharmaceutical’s GVOKE is room-temperature, liquid, stable glucagon that is ready-to-use in an emergency as well.
Key Developments:
- In July 2019, FDA approved Lilly's first nasal glucagon powder for the emergency treatment of severe hypoglycemia in children as well as adults with diabetes.
- In February 2020, Fresenius Kabi announced the launch of its Glucagon Emergency Kit, an FDA-approved. It is a cost-effective alternative to treat severe hypoglycemic cases in people with diabetes. The kit composed of glucagon for Injection 1 mg and a prefilled glass syringe with 1 mL of sterile water for injection, USP.
- In September 2019, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes. It is a first and only glucagon-like peptide-1 (GLP-1) analog in a pill for adults with type 2 diabetes who are not achieving their A1C goal with current antidiabetic treatment.
This Report covers the manufacturers' data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.
Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers. If you need more information, please contact SMI
Section 1: Definition
Section (2 3): Manufacturer Detail
✑ Novo Nordisk
✑ Eli Lilly
✑ Fresenius Kabi
✑ Torrent Labs
✑ Taj Pharmaceuticals
✑ Xeris Pharmaceuticals
Section 4: Region Segmentation
✑ North America Country (United States, Canada)
✑ South America
✑ Asia Country (China, Japan, India, Korea)
✑ Europe Country (Germany, UK, France, Italy)
✑ Other Country (Middle East, Africa, GCC)
Section (5 6 7): Segmentation
Product Type Segmentation:
✑ Inject Glucagon
✑ Nasal Glucagon
Industry Segmentation:
✑ Emergency Kits
✑ General Use
✑ Diagnostic & Motility
✑ Cardiogenic Shock
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2019-2024)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
